Cross-Sector entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Collegium, the most common co-covered peer. Each carries 12 original sources on average. We currently track 1 Cross-Sector story that mention Vericel, all published on February 26, 2026.
1 verified story tracked
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Collegium, the most common co-covered peer. Each carries 12 original sources on average. We currently track 1 Cross-Sector story that mention Vericel, all published on February 26, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Vericel. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
